BIO
Lola A. Fashoyin-Aje, M.D., M.P.H.
Senior Vice President, Head of Regulatory Oncology, Cell & Gene
Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
See solutionsWHAT WE DO
HOW WE DO IT
Get the personal, responsive, and committed approach of a small CRO, with all the benefits of a large CRO, to help you develop life-changing treatments for patients.
Learn moreStep into the world of biotech leaders and hear the untold stories behind their journeys to bring breakthrough innovations to life.
Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
See expertiseTherapeutic Expertise
Cross-Therapeutic Expertise
Our experts help you stay at the forefront of the industry - and ahead of change.
See insightsThinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Learn moreINTERESTED IN PARTICIPATING?
HEAR FROM REAL PATIENTS
TRIAL SITES
Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.
Learn moreWe are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
About ParexelWhat can we help you find today?
BIO
Senior Vice President, Head of Regulatory Oncology, Cell & Gene
Lola A. Fashoyin-Aje, M.D., M.P.H., is Senior Vice President, Head of Regulatory Oncology, Cell & Gene where she leads a team of consultants focused on consulting in these key areas of innovation and growth for Parexel.
Dr. Fashoyin-Aje is a board-certified internist and medical oncologist with over a decade of experience at the U.S. Food and Drug Administration (FDA). She most recently served as the Director of the Office of Clinical Evaluation in the Office of Therapeutic Products at the FDA Center for Biologics Evaluation and Research (CBER). In this role, she provided clinical and scientific oversight in the clinical assessment of cellular, gene, and tissue products across all indications, supervising approximately 80 physicians and clinical pharmacologists.
Prior to that she was Deputy Director in the Division of Oncology 3 (DO3) in the Office of Oncologic Diseases (OOD) at the Center for Drug Evaluation and Research (CDER), where she provided scientific and policy guidance and oversight to multidisciplinary teams reviewing drugs and biologics under development for the treatment of solid tumor malignancies (gastrointestinal, cutaneous, and sarcoma). Dr. Fashoyin-Aje was also an Associate Director at the FDA Oncology Center of Excellence at the FDA serving as executive lead for several scientific and policy initiatives to accelerate drug development, generate evidence in representative populations, and optimize multiregional clinical development programs, She has over a decade of experience applying the regulatory framework for the approval of products regulated in both medical product Centers at FDA, for common and rare diseases.
Prior to joining the FDA as a clinical reviewer and then serving as a clinical team leader, Dr. Fashoyin-Aje completed her undergraduate and graduate training at Columbia University and Yale University, respectively, and received her M.D. degree from the University of Rochester School of Medicine and Dentistry. She completed her training in internal medicine and medical oncology at Johns Hopkins.